About Intellectual Property IP Training IP Outreach IP for… IP and... IP in... Patent & Technology Information Trademark Information Industrial Design Information Geographical Indication Information Plant Variety Information (UPOV) IP Laws, Treaties & Judgements IP Resources IP Reports Patent Protection Trademark Protection Industrial Design Protection Geographical Indication Protection Plant Variety Protection (UPOV) IP Dispute Resolution IP Office Business Solutions Paying for IP Services Negotiation & Decision-Making Development Cooperation Innovation Support Public-Private Partnerships The Organization Working with WIPO Accountability Patents Trademarks Industrial Designs Geographical Indications Copyright Trade Secrets WIPO Academy Workshops & Seminars World IP Day WIPO Magazine Raising Awareness Case Studies & Success Stories IP News WIPO Awards Business Universities Indigenous Peoples Judiciaries Genetic Resources, Traditional Knowledge and Traditional Cultural Expressions Economics Gender Equality Global Health Climate Change Competition Policy Sustainable Development Goals Enforcement Frontier Technologies Mobile Applications Sports Tourism PATENTSCOPE Patent Analytics International Patent Classification ARDI – Research for Innovation ASPI – Specialized Patent Information Global Brand Database Madrid Monitor Article 6ter Express Database Nice Classification Vienna Classification Global Design Database International Designs Bulletin Hague Express Database Locarno Classification Lisbon Express Database Global Brand Database for GIs PLUTO Plant Variety Database GENIE Database WIPO-Administered Treaties WIPO Lex - IP Laws, Treaties & Judgments WIPO Standards IP Statistics WIPO Pearl (Terminology) WIPO Publications Country IP Profiles WIPO Knowledge Center WIPO Technology Trends Global Innovation Index World Intellectual Property Report PCT – The International Patent System ePCT Budapest – The International Microorganism Deposit System Madrid – The International Trademark System eMadrid Article 6ter (armorial bearings, flags, state emblems) Hague – The International Design System eHague Lisbon – The International System of Appellations of Origin and Geographical Indications eLisbon UPOV PRISMA Mediation Arbitration Expert Determination Domain Name Disputes Centralized Access to Search and Examination (CASE) Digital Access Service (DAS) WIPO Pay Current Account at WIPO WIPO Assemblies Standing Committees Calendar of Meetings WIPO Official Documents Development Agenda Technical Assistance IP Training Institutions COVID-19 Support National IP Strategies Policy & Legislative Advice Cooperation Hub Technology and Innovation Support Centers (TISC) Technology Transfer Inventor Assistance Program WIPO GREEN WIPO's Pat-INFORMED Accessible Books Consortium WIPO for Creators WIPO ALERT Member States Observers Director General Activities by Unit External Offices Job Vacancies Procurement Results & Budget Financial Reporting Oversight

How New Funding Models Tackle Challenges in the Development of Innovative Treatments for Neglected Tropical Diseases

July 1, 2022

During the past ten years, we have witnessed significant achievements in the fight against Neglected Tropical Diseases (NTDs). As of 2020, 42 countries, territories, and areas had eliminated at least one NTD. Additionally, innovative financing mechanisms for research and development (R&D) in NTDs have emerged, including the Global Health Innovative Technology Fund, the European and Developing Countries Clinical Trials Partnership and the RIGHT Fund, to attract the necessary funding to maintain progress towards elimination of neglected diseases.

research-2022-news0018-845
PHOTO: MATHIEUSTERN

Despite these achievements, funding challenges persist, and NTDs continue to have serious consequences for millions of people. The COVID-19 pandemic also had a negative impact on funding, according to the Policy Cures Research G-FINDER survey. R&D funding for NTDs dropped by 4% in 2020 compared to 2019, and clinical development funding for NTDs fell by US $124 million in 2020, a drop of 10% from 2019, mainly due to difficulties of conducting trials during lockdowns and travel restrictions.

A 2015 analysis by Philipsborn et al. found that poverty-related diseases represent 14% of the global burden of disease, yet only attract 1.3% of global R&D expenditure. Long-term underfunding has prompted the development of alternative approaches to financing, which include:

  • Push incentives that provide funding to R&D projects in advance, such as grants containing affordability clauses.
  • Pull incentives that offer rewards achievements in the R&D process, such as tax credits, cash prizes and advance market commitments.
  • Pooling mechanisms, which facilitate knowledge and technology transfer, shortening timelines and reducing development costs.
  • Public–private partnerships that provide funding to bridge research gaps.

By subsidizing the costs of R&D through the above-listed mechanisms, the costs of R&D can be delinked from the price of the medical product.

In 2011, WIPO Re:Search united the scientific expertise of academic, non-profit, and government researchers with the R&D experience of multinational pharmaceutical companies to drive innovation in medicines, vaccines, and diagnostics for NTDs, malaria, and tuberculosis. Companies participating in WIPO Re:Search agreed to grant royalty-free licenses for R&D and manufacture for the sole purpose of addressing public health needs for NTDs in least-developed countries.

Over eleven years, WIPO Re:Search facilitated more than 150 research collaborations, ten of which achieved key product development milestones (e.g. positive “hits” or activity against pathogens or drug targets of interest).

Another innovative alternative financing model is the recently announced investment by GSK of £1 billion (Pound Sterling) over the next ten years towards R&D, with an emphasis on NTDs and antimicrobial resistance. The company has set up a Global Health Unit composed of R&D Hubs. The Hubs will focus on 30 potential new vaccines and medicines, targeting 13 infectious diseases that account for more than 60% of the burden of disease in low-income countries. This model measures success by health impact alone, rather than financial return on investment.

WIPO welcomes innovative funding models that address disease areas with a significant global health burden but for which there is little prospect of a commercial return on investment.